SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
Commission File Number 000-50133
NOTIFICATION OF LATE FILING
|_| Form 10-K |_| Form 11-K |_| Form 20-F |X| Form 10-Q
|_| Form N-SAR
For Period Ended: September 30, 2004
|_| Transition Report on Form 10-K |_| Transition Report on Form 10-Q
|_| Transition Report on Form 20-F |_| Transition Report on Form N-SAR
For the Transition Period Ended: ______________________________________
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
--------------------------------------------------------------------------------
PART I
REGISTRANT INFORMATION
Full name of registrant Grant Life Sciences, Inc.
Former name if applicable Grant Ventures, Inc.
Address of principal executive office 5511 Capital Center Drive, Suite 224
City, state and zip code Raleigh, North Carolina 27606
PART II
RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the
following should be completed. (Check box if appropriate.)
(a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable
effort or expense;
(b) The subject annual report, semi-annual report, transition
report on Form 10-K, 20-F, 11-K or Form 10-Q, or portion
thereof will be filed on or before the 15th calendar day
|X| following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day
following the prescribed due date; and
(c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q,
N-SAR or the transition report portion thereof could not be filed within the
prescribed time period.
The registrant is in the process of preparing and reviewing the financial
information of the Company on a consolidated basis. The process of compiling and
disseminating the information required to be included in the Form 10-QSB for the
relevant fiscal quarter, as well as the completion of the required review of the
Company's financial information on a consolidated basis, could not be completed
without incurring undue hardship and expense. The registrant undertakes the
responsibility to file such quarterly report no later than five days after its
original date.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
John C. Wilson (919) 852-4482
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
|X| Yes |_| No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
|X| Yes |_| No
If so: attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
For the quarter ended September 30, 2004, the registrant had no revenues
and a net loss of approximately $460,400. For the quarter ended September 30,
2003, the registrant had no revenues and a net loss of approximately $65,800.
Results for the quarter ended September 30, 2004 remain subject to further
adjustment and actual results may differ significantly from the foregoing
estimates.
The $65,800 loss for the quarter ended September 30, 2003 is the net loss
of Impact Diagnostics, Inc., now a wholly owned subsidiary of the Company. The
Company acquired Impact Diagnostics on July 30, 2004.
Grant Life Sciences, Inc.
Name of Registrant as Specified in Charter.
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: November 16, 2004 By /s/ John C. Wilson
----------------------
John C. Wilson
Chief Financial Officer